Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Among authors: raab ms. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield.
Breitkreutz I, Lokhorst HM, Raab MS, Holt Bv, Cremer FW, Herrmann D, Glasmacher A, Schmidt-Wolf IG, Blau IW, Martin H, Salwender H, Haenel A, Sonneveld P, Goldschmidt H. Breitkreutz I, et al. Among authors: raab ms. Leukemia. 2007 Jun;21(6):1294-9. doi: 10.1038/sj.leu.2404661. Epub 2007 Mar 22. Leukemia. 2007. PMID: 17377586 Clinical Trial.
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Müller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H. Neben K, et al. Among authors: raab ms. Haematologica. 2010 Jul;95(7):1150-7. doi: 10.3324/haematol.2009.016436. Epub 2010 Mar 10. Haematologica. 2010. PMID: 20220069 Free PMC article.
[Immunostimulating drugs and cytokines].
Lehners N, Goldschmidt H, Raab MS. Lehners N, et al. Among authors: raab ms. Ther Umsch. 2011 Nov;68(11):655-8. doi: 10.1024/0040-5930/a000226. Ther Umsch. 2011. PMID: 22045528 Review. German.
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H. Neben K, et al. Among authors: raab ms. Blood. 2012 Jan 26;119(4):940-8. doi: 10.1182/blood-2011-09-379164. Epub 2011 Dec 8. Blood. 2012. PMID: 22160383 Free article. Clinical Trial.
193 results